184 related articles for article (PubMed ID: 21680691)
21. Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.
Chen R; Zhao Y; Huang Y; Yang Q; Zeng X; Jiang W; Liu J; Thrasher JB; Forrest ML; Li B
Prostate; 2015 May; 75(6):593-602. PubMed ID: 25620467
[TBL] [Abstract][Full Text] [Related]
22. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
Evazalipour M; D'Huyvetter M; Tehrani BS; Abolhassani M; Omidfar K; Abdoli S; Arezumand R; Morovvati H; Lahoutte T; Muyldermans S; Devoogdt N
Contrast Media Mol Imaging; 2014; 9(3):211-20. PubMed ID: 24700748
[TBL] [Abstract][Full Text] [Related]
23. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer.
Kratochwil C; Giesel FL; Leotta K; Eder M; Hoppe-Tich T; Youssoufian H; Kopka K; Babich JW; Haberkorn U
J Nucl Med; 2015 Feb; 56(2):293-8. PubMed ID: 25613537
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.
Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen Å
Clin Cancer Res; 2024 Jun; 30(11):2531-2544. PubMed ID: 38593212
[TBL] [Abstract][Full Text] [Related]
25. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
26. Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA).
El-Zaria ME; Genady AR; Janzen N; Petlura CI; Beckford Vera DR; Valliant JF
Dalton Trans; 2014 Apr; 43(13):4950-61. PubMed ID: 24481236
[TBL] [Abstract][Full Text] [Related]
27. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
[TBL] [Abstract][Full Text] [Related]
28. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
Kularatne SA; Venkatesh C; Santhapuram HK; Wang K; Vaitilingam B; Henne WA; Low PS
J Med Chem; 2010 Nov; 53(21):7767-77. PubMed ID: 20936874
[TBL] [Abstract][Full Text] [Related]
30. Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
Guo Z; Lai Y; Du T; Zhang Y; Chen J; Bi L; Lin T; Liu H; Wang W; Xu K; Jiang C; Han J; Zhang C; Dong W; Huang J; Huang H
Chin Med J (Engl); 2014; 127(5):929-36. PubMed ID: 24571890
[TBL] [Abstract][Full Text] [Related]
31. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
33. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
34. Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells.
Zhang Y; Guo Z; Du T; Chen J; Wang W; Xu K; Lin T; Huang H
Prostate; 2013 Jun; 73(8):835-41. PubMed ID: 23255296
[TBL] [Abstract][Full Text] [Related]
35. Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer.
Graham K; Lesche R; Gromov AV; Böhnke N; Schäfer M; Hassfeld J; Dinkelborg L; Kettschau G
J Med Chem; 2012 Nov; 55(22):9510-20. PubMed ID: 23025786
[TBL] [Abstract][Full Text] [Related]
36. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells.
Cao KY; Xu L; Zhang DM; Zhang XM; Zhang T; He X; Wang Z; Feng FS; Qiu SP; Shen GX
Int J Oncol; 2012 Jun; 40(6):1977-85. PubMed ID: 22322627
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
39. A low molecular weight PSMA-based fluorescent imaging agent for cancer.
Chen Y; Dhara S; Banerjee SR; Byun Y; Pullambhatla M; Mease RC; Pomper MG
Biochem Biophys Res Commun; 2009 Dec; 390(3):624-9. PubMed ID: 19818734
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
